Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

Eyal Lebel, Shlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, Batia Avni, Shlomo Elias, Miri Assayag, Tatyana Dubnikov, Nomi Zalcman, Marjorie Pick, Eran Zimran, Yael C. Cohen, Irit Avivi Mazza, Cyrille Cohen, Polina Stepensky, Moshe E Gatt

Blood (2023) 142 (Supplement 1): 538.

https://doi.org/10.1182/blood-2023-186450

Published: 2023

Journal Articles

Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience

Eyal Lebel, Vladimir Vainstein, Paolo Milani, Giovanni Palladini, Tamir Shragai, Noa Lavi, Hila Magen, Assayag Miri, Irit Avivi Mazza, Moshe E Gatt

Blood (2023) 142 (Supplement 1): 6763.

https://doi.org/10.1182/blood-2023-173317

Published: 2023

Journal Articles

Towards a Decision Engine for Therapeutic Optimization of Relapsed Refractory Multiple Myeloma

Yael C. Cohen, Mor Zada, Shuang-Yin Wang, Assaf Weiner, Natan Melamed, Polina Stepensky, Moshe E Gatt, Shlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel, Irit Avivi Mazza, Anna Gurevich Shapiro, Iuliana Vaxman, Tamir Shragai, Paulina Chalan, Eyal David, Ido Amit

Blood (2023) 142 (Supplement 1): 341.

https://doi.org/10.1182/blood-2023-190178

Published: 2023

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Yael C. Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Moshe Mittelman, Inna Tzoran, Vladimir Vainstein, Noa Lowenton-Spier, Natan Melamed, Ella Krayzler, Ilana Pereg, Irit Avivi Mazza

Blood (2023) 142 (Supplement 1): 2014.

https://doi.org/10.1182/blood-2023-185830

Published: 2023

Journal Articles

Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma

Arnon Haran, Noa Gros Even-Zohar, Eyal Lebel, Shlomzion Aumann, Adir Shaulov, Moshe E Gatt, Boaz Nachmias

Blood (2023) 142 (Supplement 1): 6277.

https://doi.org/10.1182/blood-2023-187241

Published: 2023

Journal Articles

Safety and Efficacy of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma

Eyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, Sigal Grisariu, Shlomo Elias, Miri Assayag, Tatyana Dubnikov, Nomi Zalcman, Marjorie Pick, Eran Zimran, Yael C. Cohen, Irit Avivi Mazza, Cyrille Cohen, Moshe E Gatt, Polina Stepensky

Blood (2023) 142 (Supplement 1): 4852.

https://doi.org/10.1182/blood-2023-185069

Published: 2023

Journal Articles

The Utility of a Coagulation Laboratory Profile in Addition to Clinical Risk Factors for Thrombosis Risk Evaluation in Patients with Myeloproliferative Neoplasms: A Pilot Study

Inbal Shapira, Ela Shai, Yossef Kalish, Uria Tsubary, Shlomzion Aumann, Ariela Arad, Batia Roth Jelinek, Noa Buchman, Moshe E Gatt, Eran Zimran

Blood (2023) 142 (Supplement 1): 6401.

https://doi.org/10.1182/blood-2023-187136

Published: 2023

Journal Articles

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Blood (2022) 140 (Supplement 1): 4426–4427.

https://doi.org/10.1182/blood-2022-164572

Published: 2022

Journal Articles

"Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia - a Multi-Center Retrospective Study

Gilad Itchaki, Ohad Benjamini, Mor Levi, Anatoly Nemets, Shay Yeganeh, Mahdi Assaly, Anna Gourevitch, Revital Saban, Moshe E Gatt, Pia Raanani, Iuliana Vaxman

Blood (2022) 140 (Supplement 1): 11981–11982.

https://doi.org/10.1182/blood-2022-163009

Published: 2022

Journal Articles

End-of-Life Therapeutic Burden: A Comparative Study of Hematologic and Solid Tumor Malignancies

Rachel Burstein, Adir Shaulov, Dina Ben Yehuda, Boaz Nachmias, Moshe E Gatt, Ariel Aviv

Blood (2022) 140 (Supplement 1): 10793.

https://doi.org/10.1182/blood-2022-162541

Published: 2022

Journal Articles

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Yael C Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Noa Lowenton-Spier, Liron Gez-Aaronson, Natan Melamed, Irit Avivi

Blood (2022) 140 (Supplement 1): 10131–10132.

https://doi.org/10.1182/blood-2022-164722

Published: 2022

Journal Articles

ATG-F Versus ATG-T for Graft Versus Host Disease Prevention in Allogeneic Stem Cell Transplantation: A Retrospective Comparative Study

Itay Falicovich, Boaz Nachmias, Eran Zimran, Adir Shaulov, Moshe E Gatt, Polina Stepensky, Sigal Grisariu Greenzaid, Batia Avni

Blood (2022) 140 (Supplement 1): 12876–12877.

https://doi.org/10.1182/blood-2022-164586

Published: 2022

Journal Articles

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Blood (2019) 134 (Supplement_1): 982.

https://doi.org/10.1182/blood-2019-129618

Published: 2019

Journal Articles

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Svetlana Trestman, MD, Chezi Ganzel, MD, Shai Levi, MSc, Moshe E. Gatt, MD, Noa Lavi, MD, Iuliana Vaxman, MDBA, Ory Rouvio, MD, Hila Magen, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Tamar Tadmor, MD, Katrin Herzog Tzarfati, MD, Celia Surio, MD, Shay Yeganeh, MD, Nagib Deli, MD, Irit Avivi, MD, Cohen Yael, Dr.

Blood (2019) 134 (Supplement_1): 3180.

https://doi.org/10.1182/blood-2019-128325

Published: 2019

Journal Articles

Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Blood (2018) 132 (Supplement 1): 3295.

https://doi.org/10.1182/blood-2018-99-114106

Published: 2018

Journal Articles

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Noam Benyamini, MD, Adir S, MD, Moshe E. Gatt, MD, Yael C Cohen, MD, Irit Avivi, MD, Svetlana Trestman, MD, Olga Shvetz, MD, Tamar Tadmor, MD, Najib Dally, MD, Yevgeny Chober, Hila Magen, MD, Chezi Ganzel, MD, Osnat Jarchowcky Dolberg, Celia Suriu, MD, Noa Lavi, MD

Blood (2018) 132 (Supplement 1): 3259.

https://doi.org/10.1182/blood-2018-99-115985

Published: 2018

Journal Articles

Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study

Yael C Cohen, Hila Magen, MD, Noa Lavi, MD, Moshe E. Gatt, MD, Evgeni Chubar, MD, Natalia Kreiniz, Tamar Tadmor, MD, Svetlana Trestman, MD, Roy Vitkon, MD, Ory Rouvio, Olga Shvetz, MD, Adir Shaulov, MD, Irit Avivi, MD

Blood (2018) 132 (Supplement 1): 1972.

https://doi.org/10.1182/blood-2018-99-114217

Published: 2018

Journal Articles

Characteristics and Outcome of Multiple Myeloma Patients Presenting with Anemia Only: a Retrospective Multi-Center Study

Tamir Shragai, MD, Moshe E. Gatt, MD, Adir Shaulov, MD, Eirini Katodritou, MD, Theodora Triantafyllou, MD, Noa Lavi, MD, Anastasia Pouli, MD PhD, Anastasia Sioni, Iuliana Vaxman, MD BA, Miri Zektser, MD, Chezi Ganzel, MD, Noam Benyamini, MD, Svetlana Trestman, MD, Tomer ziv Baran, PhD, Yael C Cohen, MD, Irit Avivi, MD

Blood (2018) 132 (Supplement 1): 5578.

https://doi.org/10.1182/blood-2018-99-116372

Published: 2018

Journal Articles

The Role of CD24 in Multiple Myeloma Tumorigenicity and the Effect of the Microenvironment on CD24 Expression

Moshe E. Gatt, MD, Marjorie Pick, PhD, Gilad Nechama, Jacob Bar Tana, MDPhD

Blood (2017) 130 (Supplement 1): 1765.

https://doi.org/10.1182/blood.V130.Suppl_1.1765.1765

Published: 2017

Journal Articles

Treatment Patterns and Clinical Outcomes in High-Risk Multiple Myeloma Patients Carrying the 17p Deletion: A Multi-Center Retrospective Observational Study

Yael Cohen, MD, Moshe E. Gatt, MD, Noa Lavi, MD, Chezi Ganzel, Hila Magen, MD, Irit Avivi, MD, Tamar Tadmor, MD, Celia Suriu, MD, Osnat Jarchowsky Dolberg, Amitai Papushado, MD, Svetlana Trestman, MD, Ron Ram, MD

Blood (2016) 128 (22): 4510.

https://doi.org/10.1182/blood.V128.22.4510.4510

Published: 2016

NARROW

Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis

Belantamab Mafodotin in Relapse/Refractory AL Amyloidosis- Real-Life Multi-Center Experience

Towards a Decision Engine for Therapeutic Optimization of Relapsed Refractory Multiple Myeloma

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)

Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma

Safety and Efficacy of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma

The Utility of a Coagulation Laboratory Profile in Addition to Clinical Risk Factors for Thrombosis Risk Evaluation in Patients with Myeloproliferative Neoplasms: A Pilot Study

Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

"Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia - a Multi-Center Retrospective Study

End-of-Life Therapeutic Burden: A Comparative Study of Hematologic and Solid Tumor Malignancies

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

ATG-F Versus ATG-T for Graft Versus Host Disease Prevention in Allogeneic Stem Cell Transplantation: A Retrospective Comparative Study

Kydar Multicenter Trial of Quadruple Regimen for Induction Resistant Myeloma Combined with Translational Single-Cell Analysis Identifies Potential Drivers of Advanced Resistance, Including Novel Immune Checkpoints

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study

Characteristics and Outcome of Multiple Myeloma Patients Presenting with Anemia Only: a Retrospective Multi-Center Study

The Role of CD24 in Multiple Myeloma Tumorigenicity and the Effect of the Microenvironment on CD24 Expression

Treatment Patterns and Clinical Outcomes in High-Risk Multiple Myeloma Patients Carrying the 17p Deletion: A Multi-Center Retrospective Observational Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only